Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR) : a prospective, multicentre, single-arm study
Copyright © 2024 Elsevier Ltd. All rights reserved..
BACKGROUND: Surgery remains the only recommended intervention for patients with native aortic regurgitation. A transcatheter therapy to treat patients at high risk for mortality and complications with surgical aortic valve replacement represents an unmet need. Commercial transcatheter heart valves in pure aortic regurgitation are hampered by unacceptable rates of embolisation and paravalvular regurgitation. The Trilogy transcatheter heart valve (JenaValve Technology, Irvine, CA, USA) provides a treatment option for these patients. We report outcomes with transfemoral transcatheter aortic valve implantation (TAVI) in patients with pure aortic regurgitation using this dedicated transcatheter heart valve.
METHODS: The ALIGN-AR trial is a prospective, multicentre, single-arm study. We recruited symptomatic patients (aged ≥18 years) with moderate-to-severe or severe aortic regurgitation at high risk for mortality and complications after surgical aortic valve replacement at 20 US sites for treatment with the Trilogy transcatheter heart valve. The 30-day composite primary safety endpoint was compared for non-inferiority with a prespecified performance goal of 40·5%. The primary efficacy endpoint was 1-year all-cause mortality compared for non-inferiority with a performance goal of 25%. This trial is registered with ClinicalTrials.gov, NCT04415047, and is ongoing.
FINDINGS: Between June 8, 2018, and Aug 29, 2022, we screened 346 patients. We excluded 166 (48%) patients and enrolled 180 (52%) patients with symptomatic aortic regurgitation deemed high risk by the heart team and independent screening committee assessments. The mean age of the study population was 75·5 years (SD 10·8), and 85 (47%) were female, 95 (53%) were male, and 131 (73%) were White. Technical success was achieved in 171 (95%) patients. At 30 days, four (2%) deaths, two (1%) disabling strokes, and two (1%) non-disabling strokes occurred. Using standard Valve Academic Research Consortium-2 definitions, the primary safety endpoint was achieved, with events occurring in 48 (27% [97·5% CI 19·2-34·0]) patients (pnon-inferiority<0·0001), with new pacemaker implantation in 36 (24%) patients. The primary efficacy endpoint was achieved, with mortality in 14 (7·8% [3·3-12·3]) patients at 1 year (pnon-inferiority<0·0001).
INTERPRETATION: This study shows the safety and effectiveness of treating native aortic regurgitation using a dedicated transcatheter heart valve to treat patients with symptomatic moderate-to-severe or severe aortic regurgitation who are at high risk for mortality or complications after surgical aortic valve replacement. The observed short-term clinical and haemodynamic outcomes are promising as are signs of left ventricular remodelling, but long-term follow-up is necessary.
FUNDING: JenaValve Technology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:403 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 403(2024), 10435 vom: 13. Apr., Seite 1451-1459 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vahl, Torsten P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT04415047 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(23)02806-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370421809 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370421809 | ||
| 003 | DE-627 | ||
| 005 | 20240415233612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240331s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(23)02806-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM370421809 | ||
| 035 | |a (NLM)38552656 | ||
| 035 | |a (PII)S0140-6736(23)02806-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vahl, Torsten P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR) |b a prospective, multicentre, single-arm study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04415047 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Surgery remains the only recommended intervention for patients with native aortic regurgitation. A transcatheter therapy to treat patients at high risk for mortality and complications with surgical aortic valve replacement represents an unmet need. Commercial transcatheter heart valves in pure aortic regurgitation are hampered by unacceptable rates of embolisation and paravalvular regurgitation. The Trilogy transcatheter heart valve (JenaValve Technology, Irvine, CA, USA) provides a treatment option for these patients. We report outcomes with transfemoral transcatheter aortic valve implantation (TAVI) in patients with pure aortic regurgitation using this dedicated transcatheter heart valve | ||
| 520 | |a METHODS: The ALIGN-AR trial is a prospective, multicentre, single-arm study. We recruited symptomatic patients (aged ≥18 years) with moderate-to-severe or severe aortic regurgitation at high risk for mortality and complications after surgical aortic valve replacement at 20 US sites for treatment with the Trilogy transcatheter heart valve. The 30-day composite primary safety endpoint was compared for non-inferiority with a prespecified performance goal of 40·5%. The primary efficacy endpoint was 1-year all-cause mortality compared for non-inferiority with a performance goal of 25%. This trial is registered with ClinicalTrials.gov, NCT04415047, and is ongoing | ||
| 520 | |a FINDINGS: Between June 8, 2018, and Aug 29, 2022, we screened 346 patients. We excluded 166 (48%) patients and enrolled 180 (52%) patients with symptomatic aortic regurgitation deemed high risk by the heart team and independent screening committee assessments. The mean age of the study population was 75·5 years (SD 10·8), and 85 (47%) were female, 95 (53%) were male, and 131 (73%) were White. Technical success was achieved in 171 (95%) patients. At 30 days, four (2%) deaths, two (1%) disabling strokes, and two (1%) non-disabling strokes occurred. Using standard Valve Academic Research Consortium-2 definitions, the primary safety endpoint was achieved, with events occurring in 48 (27% [97·5% CI 19·2-34·0]) patients (pnon-inferiority<0·0001), with new pacemaker implantation in 36 (24%) patients. The primary efficacy endpoint was achieved, with mortality in 14 (7·8% [3·3-12·3]) patients at 1 year (pnon-inferiority<0·0001) | ||
| 520 | |a INTERPRETATION: This study shows the safety and effectiveness of treating native aortic regurgitation using a dedicated transcatheter heart valve to treat patients with symptomatic moderate-to-severe or severe aortic regurgitation who are at high risk for mortality or complications after surgical aortic valve replacement. The observed short-term clinical and haemodynamic outcomes are promising as are signs of left ventricular remodelling, but long-term follow-up is necessary | ||
| 520 | |a FUNDING: JenaValve Technology | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Thourani, Vinod H |e verfasserin |4 aut | |
| 700 | 1 | |a Makkar, Raj R |e verfasserin |4 aut | |
| 700 | 1 | |a Hamid, Nadira |e verfasserin |4 aut | |
| 700 | 1 | |a Khalique, Omar K |e verfasserin |4 aut | |
| 700 | 1 | |a Daniels, David |e verfasserin |4 aut | |
| 700 | 1 | |a McCabe, James M |e verfasserin |4 aut | |
| 700 | 1 | |a Satler, Lowell |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a George, Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Aldea, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Sheridan, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Kereiakes, Dean |e verfasserin |4 aut | |
| 700 | 1 | |a Golwala, Harsh |e verfasserin |4 aut | |
| 700 | 1 | |a Zahr, Firas |e verfasserin |4 aut | |
| 700 | 1 | |a Chetcuti, Stanley |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Pradeep |e verfasserin |4 aut | |
| 700 | 1 | |a Kodali, Susheel K |e verfasserin |4 aut | |
| 700 | 1 | |a Treede, Hendrik |e verfasserin |4 aut | |
| 700 | 1 | |a Baldus, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Amoroso, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Ranard, Lauren S |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Duane S |e verfasserin |4 aut | |
| 700 | 1 | |a Leon, Martin B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 403(2024), 10435 vom: 13. Apr., Seite 1451-1459 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:403 |g year:2024 |g number:10435 |g day:13 |g month:04 |g pages:1451-1459 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(23)02806-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 403 |j 2024 |e 10435 |b 13 |c 04 |h 1451-1459 | ||